List of Tiglutik Kit drug patents

Tiglutik Kit is owned by Italfarmaco Spa.

Tiglutik Kit contains Riluzole.

Tiglutik Kit has a total of 1 drug patent out of which 0 drug patents have expired.

Tiglutik Kit was authorised for market use on 05 September, 2018.

Tiglutik Kit is available in suspension;oral dosage forms.

Tiglutik Kit can be used as a method of treating amyotrophic lateral sclerosis in a patient in need of such treatment, said method comprising administering to said patient an effective amount of a suspension according to claim 1.

The generics of Tiglutik Kit are possible to be released after 12 March, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8765150 ITALFARMACO SPA Riluzole aqueous suspensions
Mar, 2029

(6 years from now)

Drugs and Companies using RILUZOLE ingredient

Market Authorisation Date: 05 September, 2018

Treatment: A method of treating amyotrophic lateral sclerosis in a patient in need of such treatment, said method comprising administering to said patient an effective amount of a suspension according to claim 1

Dosage: SUSPENSION;ORAL

How can I launch a generic of TIGLUTIK KIT before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic